Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03957954 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Therapy for Limbal Stem Cell Deficiency
A Phase 1 study of Limbal Stem Cell Deficiency, sponsored by University of California, Los Angeles.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03957954: Active Phase 1 study of Limbal Stem Cell Deficiency, sponsored by University of California, Los Angeles.
NCT03957954 is a Phase 1 study of Limbal Stem Cell Deficiency that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03957954, a Phase 1 study of Limbal Stem Cell Deficiency, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I study will collect preliminary information on the activity and safety of cLSC. We will investigate the ability to manufacture and transplant cLSC onto the cornea successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular surface (efficacy) without serious adverse events (safety).
Primary Outcome
Safety assessed by incidence of Serious Adverse Events (SAEs) directly related to cLSC: infection and/or corneal perforation.
Conditions Studied
Interventions
- BIOLOGICAL cLSC
- DEVICE Scleral contact lens (SCL)
Study Locations (1)
California
- University of California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 1 |
What the registry record for NCT03957954 still lists
NCT03957954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Limbal Stem Cell Deficiency appearing as the primary indexed condition, and to 2 interventions - of which cLSC is the first listed.
NCT03957954 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03957954 about?
NCT03957954 is a clinical study titled "Stem Cell Therapy for Limbal Stem Cell Deficiency". This phase I study will collect preliminary information on the activity and safety of cLSC. We will investigate the ability to manufacture and transplant cLSC onto the cornea successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular surface (efficacy) without seri...
What is the current status of trial NCT03957954?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-09-30. Estimated completion is 2027-04-30.
What conditions does trial NCT03957954 study?
This clinical trial studies the following conditions: Limbal Stem Cell Deficiency.
What interventions are being tested in trial NCT03957954?
The interventions under investigation include: cLSC (BIOLOGICAL), Scleral contact lens (SCL) (DEVICE).
Who is sponsoring clinical trial NCT03957954?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03957954 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Limbal Stem Cell Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03957954's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI